NASDAQ$IRON
Disc Medicine Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Disc Medicine became publicly traded through reverse merger, strengthened balance sheet, and progressed bitopertin and DISC-0974 into patient studies.
Disc Medicine reported its full year 2022 financial results, highlighting its transformation into a publicly-traded company through a reverse merger with Gemini Therapeutics. The company ended the year with $194.6 million in cash and cash equivalents and advanced its pipeline programs, including bitopertin and DISC-0974, into clinical studies.
- Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON”.
- Ended 2022 with approximately $194.6 million in cash and cash equivalents.
- Initiated two Phase 2 trials, AURORA and BEACON, for bitopertin in erythropoietic protoporphyria (EPP).
- Initiated Phase 1b/2 studies of DISC-0974 in myelofibrosis (MF) patients with anemia and in patients with anemia of chronic kidney disease.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
Disc Medicine expects to present interim data from the BEACON study in the first half of 2023 and topline data from the AURORA study by year-end 2023. Interim data from the Phase 1b/2 studies of DISC-0974 in myelofibrosis and NDD-CKD patients are expected by the end of 2023. The company anticipates these combined cash and cash equivalents to fund its operational plans into 2025.
Tailwinds
- Interim data from BEACON study expected in 1H 2023.
- Topline data from AURORA study expected by year-end 2023.
- Interim data from DISC-0974 Phase 1b/2 studies expected by year-end 2023.
- Initiate a Phase 1 study of MWTX-003 in healthy volunteers during the second half of 2023.
- Cash and cash equivalents expected to fund operational plans into 2025.
Headwinds
- Difficulty in predicting the time and cost of development of product candidates.
- Clinical trial results may not be predictive of future results.
- The company may not be able to identify additional product candidates with significant commercial potential.
- Adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials
- Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro